A A Fox - JoVE Visualize

Showing results (431-440 of 491) with videos related to

Pageof 50

Sort By:

JAMA|November 3, 2012

Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudyPaul A Gurbel, David Erlinge, E Magnus Ohman, et al.

European Heart Journal|August 24, 2014

Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trialGünter Breithardt, Helmut Baumgartner, Scott D Berkowitz, et al.

Journal of the American College of Cardiology|September 21, 2019

Major Bleeding in Patients With Coronary or Peripheral Artery Disease Treated With Rivaroxaban Plus AspirinJohn W Eikelboom, Jacqueline J Bosch, Stuart J Connolly, et al.

European Heart Journal|July 1, 2011

Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of CardiologyPhilippe Gabriel Steg, Kurt Huber, Felicita Andreotti, et al.

Journal of the American College of Cardiology|July 2, 2021

Mortality Benefit of Rivaroxaban Plus Aspirin in Patients With Chronic Coronary or Peripheral Artery DiseaseJohn W Eikelboom, Deepak L Bhatt, Keith A A Fox, et al.

BMJ Open|December 24, 2017

Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulationKeith A A Fox, Joseph E Lucas, Karen S Pieper, et al.

JAMA|July 9, 2004

Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trialMichael A Blazing, James A de Lemos, Harvey D White, et al.

The New England Journal of Medicine|March 27, 2012

Vorapaxar in the secondary prevention of atherothrombotic eventsDavid A Morrow, Eugene Braunwald, Marc P Bonaca, et al.

Nature Reviews. Cardiology|January 19, 2020

Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular diseaseDavide Capodanno, Deepak L Bhatt, John W Eikelboom, et al.

European Heart Journal. Cardiovascular Pharmacotherapy|March 4, 2023

Within and beyond 12-month efficacy and safety of antithrombotic strategies in patients with established coronary artery disease: two companion network meta-analyses of the 2022 joint clinical consensus statement of the European Association of Percutaneous Cardiovascular Interventions (EAPCI), European Association for Acute CardioVascular Care (ACVC), and European Association of Preventive Cardiology (EAPC)Eliano Pio Navarese, Antonio Landi, Angelo Oliva, et al.

Pageof 50

Showing results (431-440 of 491) with videos related to

Sort By:

Pageof 50

JAMA|November 3, 2012

Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudyPaul A Gurbel, David Erlinge, E Magnus Ohman, et al.

European Heart Journal|August 24, 2014

Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trialGünter Breithardt, Helmut Baumgartner, Scott D Berkowitz, et al.

Journal of the American College of Cardiology|September 21, 2019

Major Bleeding in Patients With Coronary or Peripheral Artery Disease Treated With Rivaroxaban Plus AspirinJohn W Eikelboom, Jacqueline J Bosch, Stuart J Connolly, et al.

European Heart Journal|July 1, 2011

Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of CardiologyPhilippe Gabriel Steg, Kurt Huber, Felicita Andreotti, et al.

Journal of the American College of Cardiology|July 2, 2021

Mortality Benefit of Rivaroxaban Plus Aspirin in Patients With Chronic Coronary or Peripheral Artery DiseaseJohn W Eikelboom, Deepak L Bhatt, Keith A A Fox, et al.

BMJ Open|December 24, 2017

Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulationKeith A A Fox, Joseph E Lucas, Karen S Pieper, et al.

JAMA|July 9, 2004

Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trialMichael A Blazing, James A de Lemos, Harvey D White, et al.

The New England Journal of Medicine|March 27, 2012

Vorapaxar in the secondary prevention of atherothrombotic eventsDavid A Morrow, Eugene Braunwald, Marc P Bonaca, et al.

Nature Reviews. Cardiology|January 19, 2020

Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular diseaseDavide Capodanno, Deepak L Bhatt, John W Eikelboom, et al.

European Heart Journal. Cardiovascular Pharmacotherapy|March 4, 2023

Within and beyond 12-month efficacy and safety of antithrombotic strategies in patients with established coronary artery disease: two companion network meta-analyses of the 2022 joint clinical consensus statement of the European Association of Percutaneous Cardiovascular Interventions (EAPCI), European Association for Acute CardioVascular Care (ACVC), and European Association of Preventive Cardiology (EAPC)Eliano Pio Navarese, Antonio Landi, Angelo Oliva, et al.

Pageof 50